HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Burden, D. A. Articles by Osheroff, N. Search for Related Content PubMed PubMed Citation Articles by Burden, D. A. Articles by Osheroff, N. Social Bookmarking                      What's this?

J Biol Chem, Vol. 274, Issue 8, 5227-5235, February 19, 1999

In Vitro Evolution of Preferred Topoisomerase II DNA Cleavage Sites

D. Andrew Burden and Neil Osheroff^¶

From the Departments of  Biochemistry and ^¶ Medicine (Oncology), Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146

Topoisomerase II is an essential enzyme that is the target for several clinically important anticancer drugs. Although this enzyme must create transient double-stranded breaks in the genetic material in order to carry out its indispensable DNA strand passage reaction, the factors that underlie its nucleotide cleavage specificity remain an enigma. Therefore, to address the critical issue of enzyme specificity, a modified systematic evolution of ligands by exponential enrichment (SELEX) protocol was employed to select/evolve DNA sequences that were preferentially cleaved by Drosophila melanogaster topoisomerase II. Levels of DNA scission rose substantially (from 3 to 20%) over 20 rounds of SELEX. In vitro selection/evolution converged on an alternating purine/pyrmidine sequence that was highly AT-rich (TATATATACATATATATA). The preference for this sequence was more pronounced for Drosophila topoisomerase II over other species and was increased in the presence of DNA cleavage-enhancing anticancer drugs. Enhanced cleavage appeared to be based on higher rates of DNA scission rather than increased binding affinity or decreased religation rates. The preferred sequence for topoisomerase II-mediated DNA cleavage is dramatically overrepresented (~10,000-fold) in the euchromatic genome of D. melanogaster, implying that it may be a site for the physiological action of this enzyme.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				F. Mueller-Planitz and D. Herschlag DNA topoisomerase II selects DNA cleavage sites based on reactivity rather than binding affinity Nucleic Acids Res., June 28, 2007; 35(11): 3764 - 3773. [Abstract] [Full Text] [PDF]

				P. Freede and S. Brantl Transcriptional Repressor CopR: Use of SELEX To Study the copR Operator Indicates that Evolution Was Directed at Maximal Binding Affinity J. Bacteriol., September 15, 2004; 186(18): 6254 - 6264. [Abstract] [Full Text] [PDF]

				C. E. Perrone, K. C. Takahashi, and G. M. Williams Inhibition of Human Topoisomerase II{alpha} by Fluoroquinolones and Ultraviolet A Irradiation Toxicol. Sci., September 1, 2002; 69(1): 16 - 22. [Abstract] [Full Text] [PDF]

				M. Hakli, U. Karvonen, O. A. Janne, and J. J. Palvimo The RING Finger Protein SNURF Is a Bifunctional Protein Possessing DNA Binding Activity J. Biol. Chem., June 22, 2001; 276(26): 23653 - 23660. [Abstract] [Full Text] [PDF]